Loyal licenses oral IGF-1 pill

Licensing an oral IGF-1 drug from Crinetics let Loyal turn a hard biotech problem into a product design choice. Instead of relying only on a clinic injection for large dogs, Loyal added a daily pill that targets the same biology, lowering manufacturing and distribution complexity and making long term treatment look more like a standard chronic prescription filled through vets.

• The underlying idea is simple, large and giant dogs stay bigger in part because IGF-1 signaling runs higher, and that same pathway is linked to their shorter lifespan. Loyal is building both LOY-001 and LOY-003 around reducing that signal, then packaging it in two formats for the same use case.
  1 loyal 2 sacra 5 nih 6 nih
• Crinetics brought in the molecule, Loyal brought in the dog aging program. The partnership gave Loyal a worldwide exclusive veterinary license to CRN01941, renamed LOY-003, while Crinetics gained access to Loyal's dog data. That is a classic biotech asset license, one side supplies the compound, the other supplies the indication and development path.
  1 loyal 7 crinetics
• The pill format matters commercially. Loyal has said oral delivery should be cheaper to make and distribute than an injectable. In practice that can widen the market from owners willing to schedule periodic vet administered shots to owners and vets comfortable managing a daily medication, much closer to how other long term pet drugs are used.
  1 loyal 3 loyal 4 businesswire

Going forward, the key advantage is not just having an aging drug, but having multiple formats wrapped around the same mechanism. If Loyal reaches market, the company can match treatment to owner behavior and veterinary workflow, which should make IGF-1 reduction in large dogs easier to prescribe, refill, and scale across routine care.